BiotechTubeBiotechTube
Home/Pipeline/AGEN2373 (CD137 Agonist)

AGEN2373 (CD137 Agonist)

Not specified

Not specifiedPipeline asset

Key Facts

Indication
Not specified
Phase
Not specified
Status
Pipeline asset
Company
Agenus

About Agenus

Agenus is focused on developing novel immunotherapies designed to overcome the limitations of first-generation checkpoint inhibitors, particularly in 'cold' or immunologically resistant tumors. The company's most advanced asset, the BOT/BAL combination, has shown promising activity in multiple solid tumors and is now entering registrational studies. With a 30-year legacy in immunotherapy, Agenus leverages a multi-faceted platform to create treatments that aim to deliver deeper and more durable responses for cancer patients.

View full company profile

Therapeutic Areas

Oncology

Other Not specified Drugs

DrugCompanyPhase
Inflammation ProgramsArcus BiosciencesNot Specified
Bone Marrow Conditioning ProgramTelix PharmaceuticalsPipeline
AGMB-447Agomab TherapeuticsNot Disclosed
AGMB-101Agomab TherapeuticsNot Disclosed
TRIFERTY-ATM®Laboratorio Reig JofreApproved/Commercial
AGEN1571 (anti-ILT2)AgenusNot specified
AGEN1777AgenusNot specified
AGEN1721AgenusNot specified
INCAGN1876 (GITR Agonist)AgenusNot specified
INCAGN1949 (OX40 Agonist)AgenusNot specified
AGEN1327 (anti-TIGIT)AgenusNot specified
AGENT-797 (iNKT Cell Therapy)AgenusNot specified